Triple Receptor Agonist

The
most
potent
GLP-1.

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously — delivering the strongest weight loss results in clinical history.

Phase 3
💉
Retatrutide
2mg / vial
24.2%
Body weight lost
Triple
Receptor agonist
48wk
Phase 2 trial
Research peptide
Retatrutide
LY3437943 · Triple GLP-1/GIP/Glucagon receptor agonist
For research use only
★★★★★ 4.9 · 843 reviews Verified
Concentration 2mg
2mg
5mg
10mg
12mg
Pack size 1 Vial
1 Vial
4 Vials −10%
10 Vials −18%
Quantity
€69 €69
Save €0
You save on this order!
🔒
SSL Secure
🚚
Cold-chain ship
↻
30-day returns
🧪
HPLC certified
🧬
HPLC Verified
99.9% purity, COA on request
💉
Lyophilized
Stable 2yr frozen, 30d reconstituted
❄
Cold-chain
Arrives refrigerated
🌎
Ships from Spain
No EU customs delays

How it works

Retatrutide's triple-agonist mechanism delivers results no single or dual agonist can match.

1

Reconstitute

Mix with bacteriostatic water as per protocol. Store refrigerated at 4°C after reconstitution.

2

Inject weekly

Subcutaneous injection once per week. Start low, titrate up over 4–8 weeks to target dose.

3

Triple activation

Simultaneously activates GLP-1, GIP, and glucagon receptors for maximal metabolic effect.

4

Track results

Most users see significant changes within 4–8 weeks. Average 24% body weight reduction at 48 weeks.

The mechanism

Triple receptor activation that outperforms everything else on the market.

Active compound
🧬
Retatrutide
LY3437943
GLP-1 receptor
GIP receptor
Glucagon receptor

Triple receptor agonist

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), Retatrutide activates three distinct metabolic receptors simultaneously — achieving deeper appetite suppression, greater fat oxidation, and superior glycemic control.

GLP-1 agonism

Reduces appetite, slows gastric emptying, improves insulin secretion

GIP agonism

Enhances fat metabolism, amplifies the GLP-1 effect on weight loss

Glucagon agonism

Increases energy expenditure, drives lipolysis in adipose tissue

Clinical trial data

Phase 2 results published in New England Journal of Medicine, 2023.

24.2%
Average body weight reduction at 48 weeks — highest dose group (12mg)
100%
Of participants in the 12mg group achieved at least 5% weight loss
83%
Achieved at least 10% body weight loss — vs 10% for placebo group
Reference: Jastreboff AM et al. "Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes." NEJM 2023. For informational purposes only. These compounds are for research use.

Choose your dose

Match your vial concentration to your protocol. Standard titration starts at 2mg and escalates over 8–12 weeks.

Starter
2mg
Weekly · weeks 1–4
✓
Ideal for titration start
✓
Minimal side effects
✓
Best for beginners
€69 / vial
Most popular
Maintenance
5mg
Weekly · weeks 4–12
✓
Optimal efficacy range
✓
Strong weight loss signal
✓
Used in Phase 2 trials
€119 / vial
Advanced
12mg
Weekly · weeks 12+
✓
Maximum efficacy dose
✓
24.2% avg weight loss
✓
Phase 2 highest dose group
€229 / vial

Why RetaLab?

The most rigorous quality standards in the research peptide space.

🧬

99.9% purity

HPLC-verified purity in every batch. Full Certificate of Analysis available for every order. No shortcuts.

💉

Lyophilized peptide

Freeze-dried for maximum shelf life and stability. 2 years frozen, 30 days at 4°C once reconstituted.

❄

Cold-chain delivery

Ships from Spain with refrigerated packaging and ice packs. Arrives at full potency every time.

📋

Full transparency

Every vial includes a QR code linking to its batch COA. Scan to verify your peptide before use.

🌎

EU warehouse

Dispatched from Spain within 48 hours. No customs, no delays, 2–4 day delivery across Europe.

👩‍⚕

Protocol support

Our team includes certified pharmacists who can help you design a safe, effective research protocol.

Retatrutide vs the rest

Why researchers are choosing triple agonism over single and dual options.

Semaglutide / Ozempic
✕
Single receptor — GLP-1 only
✕
~15% weight loss maximum
✕
No glucagon receptor activation
✕
Lower energy expenditure
✕
Plateau after ~6 months
Retatrutide
✓
Triple receptor — GLP-1+GIP+GCG
✓
24.2% weight loss at 48 weeks
✓
Full glucagon-driven lipolysis
✓
Higher resting energy expenditure
✓
Continued effect beyond 48 weeks

Researcher reviews

Verified purchases from research professionals across Europe.

843
Verified orders
4.9★
Average rating
96%
Would reorder
14
EU countries
★★★★★
"Purity is outstanding — COA matched exactly what I expected. Results at 5mg are remarkable within 6 weeks. Will be reordering the 10-pack."
DM
Dr. David M. Verified
Berlin, Germany · 3 weeks ago
★★★★★
"Fastest dispatch I've seen — arrived cold in 3 days from Spain. Quality is pharmaceutical-grade. Exactly what the NEJM data describes."
SR
Sofia R. Verified
Amsterdam · 1 month ago
★★★★★
"Started at 2mg, now at 8mg. Steady titration, zero quality issues. Support team helped me build the full protocol. Highly recommend."
KL
Karim L. Verified
Madrid, Spain · 2 weeks ago

Frequently asked

Everything researchers need to know before ordering.

Retatrutide (LY3437943) is a triple receptor agonist developed by Eli Lilly that simultaneously targets GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical trials and showed 24.2% average body weight reduction in Phase 2. Sold here for research purposes only.
Semaglutide activates one receptor (GLP-1 only). Tirzepatide activates two (GLP-1 + GIP). Retatrutide activates three (GLP-1 + GIP + Glucagon), producing significantly greater weight loss. Phase 2 data shows ~24% vs ~15% for semaglutide at comparable durations.
Standard titration: start at 2mg/week for weeks 1–4, escalate to 4–6mg for weeks 4–12, then to 8–12mg for maintenance. Always consult a healthcare professional. Our pharmacist support team can help you design a protocol.
Shipped lyophilized in cold-chain packaging with ice packs from Spain. Shelf life is 2 years frozen. Once reconstituted with bacteriostatic water, store at 4°C and use within 28–30 days.
We ship to 14 EU countries including Spain, France, Germany, Netherlands, Portugal, Belgium, Italy and more. Orders dispatched within 48 hours. EU delivery 2–5 business days.
Yes. Every batch is HPLC-tested by an independent third-party lab. Your vial includes a QR code linking directly to your batch COA. You can also request the full report by emailing our team.

Research the future
of metabolic science.

Join 843+ researchers across Europe who trust RetaLab for pharmaceutical-grade Retatrutide, cold-chain delivered from Spain.

Place your order
Retatrutide 2mg · 1 Vial
1× Retatrutide 2mg€69
ShippingFree
Total€69
Your info
Shipping address
Payment method
💳
PayPal
Instant
€credit;
💳;
💳
Credit Card
Visa / MC
🏭
Bank Transfer
SEPA / IBAN
✓

Order received!

Thank you! We have received your order.
We will contact you shortly via WhatsApp or Email to confirm and send you the payment details.

Disclaimer: Retatrutide is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not approved by the EMA or FDA for therapeutic use. RetaLab makes no medical claims. By purchasing, you confirm that you are a qualified researcher and that you will comply with all applicable laws in your jurisdiction.